Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia-Reference-Cited by-同舟云学术

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Published:2016-08-04 Issue:5 Volume:128 Page:686-698
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Metzeler Klaus H.¹²³^ORCID,Herold Tobias¹²³^ORCID,Rothenberg-Thurley Maja¹,Amler Susanne⁴,Sauerland Maria C.⁴,Görlich Dennis⁴,Schneider Stephanie¹,Konstandin Nikola P.¹,Dufour Annika¹,Bräundl Kathrin¹²³,Ksienzyk Bianka¹,Zellmeier Evelyn¹,Hartmann Luise¹²³,Greif Philipp A.¹²³,Fiegl Michael¹,Subklewe Marion¹²³,Bohlander Stefan K.⁵,Krug Utz⁶,Faldum Andreas⁴,Berdel Wolfgang E.⁷,Wörmann Bernhard⁸,Büchner Thomas⁷,Hiddemann Wolfgang¹²³,Braess Jan⁹,Spiekermann Karsten¹²³^ORCID

Affiliation:

1. Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;

2. German Cancer Consortium (DKTK), Heidelberg, Germany;

3. German Cancer Research Center (DKFZ), Heidelberg, Germany;

4. Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany;

5. Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand;

6. Department of Internal Medicine 3, Klinikum Leverkusen, Leverkusen, Germany;

7. Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany;

8. Department of Medicine, Hematology, Oncology, Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; and

9. Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany

Abstract

Key Points We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years. Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients <60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/5/686/1398120/686.pdf

Reference45 articles.

1. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.;Ley;Nature,2008

2. DNMT3A mutations in acute myeloid leukemia.;Ley;N Engl J Med,2010

3. Recurring mutations found by sequencing an acute myeloid leukemia genome.;Mardis;N Engl J Med,2009

4. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.;Cancer Genome Atlas Research Network;N Engl J Med,2013

Cited by 414 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A machine learning model identifies M3-like subtype in AML based on PML/RARα targets;iScience;2024-02

2. Acute myeloid leukemia patients with high-risk karyotypes benefit from decitabine in combination with modified CAG;2024-01-08

3. Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide;Bone Marrow Transplantation;2024-01-05

4. Clinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report;Cancer Genetics;2024-01

5. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG;Blood;2023-12-07